Parkinson's focus Herantis is a clinical-stage biotechnology company targeting disease-modifying therapies for Parkinson's disease, with lead candidate HER-096 advancing to Phase 2a in 2026 and early dataset presentations at major conferences, presenting a potential for partnerships or co-development in PD.

Clinical progression Phase 1b data indicate HER-096 is generally safe and well tolerated, with plans to evaluate efficacy and safety in a Phase 2 trial, suggesting opportunities to engage in CRO partnerships, investigator-initiated studies, and potential early-access or biomarker collaboration programs.

Strategic partnerships Recent collaborations and CRO engagement with CTC Clinical Trial Consultants and a broadened PD-focused research footprint via a PoC trial with Indivi AG signal openness to co-development, licensing, and research collaboration opportunities.

Funding signals Significant recent financing and grants totaling around €8-9 million and additional disclosed funding, indicating available runway for collaborations, joint ventures, or option-based deals with larger biopharma seeking late-stage PD candidates or biomarker programs.

Global exposure Active participation in international PD and neurodegenerative disease conferences and ongoing biomarker projects position Herantis for partnerships in research alliances, distribution discussions, and potential access to global commercialization channels as the program matures.